Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum
To evaluate the effect of rosiglitazone in a murine model of liver fibrosis induced by Schistosoma japonicum infection. A total of 50 mice were randomly and averagely divided into groups A, B, C, D and E. The mice in group A served as normal controls, while those in the other four groups were infect...
Gespeichert in:
| Veröffentlicht in: | World journal of gastroenterology : WJG 2008-05, Vol.14 (18), p.2905-2911 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2911 |
|---|---|
| container_issue | 18 |
| container_start_page | 2905 |
| container_title | World journal of gastroenterology : WJG |
| container_volume | 14 |
| creator | Chen, Hui He, Yong-Wen Liu, Wen-Qi Zhang, Jing-Hui |
| description | To evaluate the effect of rosiglitazone in a murine model of liver fibrosis induced by Schistosoma japonicum infection.
A total of 50 mice were randomly and averagely divided into groups A, B, C, D and E. The mice in group A served as normal controls, while those in the other four groups were infected with Schistosoma japonicum to induce the model of liver fibrosis. Besides, the mice in groups C, D and E were treated with praziquantel, rosiglitazone and praziquantel plus rosiglitazone, respectively. NF-kappaB binding activity and expression of PPAR gamma-mRNA were determined by Western blot assay and real-time quantitative PCR. Radioimmunonassay technique was used to detect the serum content changes of TNF-alpha and IL-6. Histological specimens were stained with HE. Expression of TGF-beta1, a-smooth muscle actin and type I and type III collagen was detected by immunohistochemistry and multimedia color pathographic analysis system.
Inflammation and fibrosis in the rosiglitazone plus praziquantel treatment group (group E) were lightest among the mice infected with Schistosoma (P < 0.05). To further explore the mechanism of rosiglitazone action, we found that rosiglitazone can significantly increase the expression of PPAR gamma [E: -18.212 +/- (-3.909) vs B: -27.315 +/- (-6.348) and C: -25.647 +/- (-5.694), P < 0.05], reduce the NF-kappaB binding activity (E: 88.89 +/- 19.34 vs B: 141.11 +/- 15.37, C: 112.89 +/- 20.17 and D: 108.89 +/- 20.47, P < 0.05), and lower the serum level of TNF-alpha (E: 1.613 +/- 0.420 ng/mL vs B: 2.892 +/- 0.587 ng/mL, C: 2.346 +/- 0.371 ng/mL and D: 2.160 +/- 0.395 ng/mL, P < 0.05) and IL-6 (E: 0.106 +/- 0.021 ng/mL vs B: 0.140 +/- 0.031 ng/mL and C: 0.137 +/- 0.027 ng/mL, P < 0.05) in mice with liver fibrosis. Rosiglitazone can also substantially reduce the hepatic expression of TGF-beta1, alpha-SMA type I and type III collagen in mice with liver fibrosis.
The activation of PPAR gamma by its ligand can retard liver fibrosis and suggest the use of rosiglitazone for the treatment of liver fibrosis due to Schistosoma japonicum infection. |
| doi_str_mv | 10.3748/wjg.14.2905 |
| format | Article |
| fullrecord | <record><control><sourceid>wanfang_jour_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2710736</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><wanfj_id>wjg200818021</wanfj_id><sourcerecordid>wjg200818021</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-eed46a41d12c1e08fe0008ee2746f4c0a10c1201a10fe9a739cd337d085497963</originalsourceid><addsrcrecordid>eNpVkUtLAzEURrNQrFZX7mUW4kZabx5tZjaCFF8gCD7WIc3caVNmkjGZUfTXm9LiY3W55PDlcD9CjimMuRT5xcdqMaZizAqY7JB9CiBHBWdyQA5iXAEwzidsjwxoLiQXtNgnj08-2kVtO_3lHWZtwHd0XcyaPti0L7HVnTVZZechgTGzruwNltn8M3s2Sxs7H32js5VuvbOmbw7JbqXriEfbOSSvN9cvs7vRw-Pt_ezqYWQE5N0IsRRTLWhJmaEIeYUAkCMyKaaVMKApGMqApllhoSUvTMm5LCGfiEIWUz4kl5vctp83WJokHXSt2mAbHT6V11b9f3F2qRb-XTFJQfJ1wOkm4EO7SruFWvk-uKSs0g1ZkqE5MJqws-0_wb_1GDvV2GiwrrVD30clQbJ8CiKB5xvQpEPFgNWPCwW17madq6hQ624SffJX_5fdFsO_Ac3ljfo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70728604</pqid></control><display><type>article</type><title>Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum</title><source>MEDLINE</source><source>Baishideng "World Journal of" online journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Chen, Hui ; He, Yong-Wen ; Liu, Wen-Qi ; Zhang, Jing-Hui</creator><creatorcontrib>Chen, Hui ; He, Yong-Wen ; Liu, Wen-Qi ; Zhang, Jing-Hui</creatorcontrib><description>To evaluate the effect of rosiglitazone in a murine model of liver fibrosis induced by Schistosoma japonicum infection.
A total of 50 mice were randomly and averagely divided into groups A, B, C, D and E. The mice in group A served as normal controls, while those in the other four groups were infected with Schistosoma japonicum to induce the model of liver fibrosis. Besides, the mice in groups C, D and E were treated with praziquantel, rosiglitazone and praziquantel plus rosiglitazone, respectively. NF-kappaB binding activity and expression of PPAR gamma-mRNA were determined by Western blot assay and real-time quantitative PCR. Radioimmunonassay technique was used to detect the serum content changes of TNF-alpha and IL-6. Histological specimens were stained with HE. Expression of TGF-beta1, a-smooth muscle actin and type I and type III collagen was detected by immunohistochemistry and multimedia color pathographic analysis system.
Inflammation and fibrosis in the rosiglitazone plus praziquantel treatment group (group E) were lightest among the mice infected with Schistosoma (P < 0.05). To further explore the mechanism of rosiglitazone action, we found that rosiglitazone can significantly increase the expression of PPAR gamma [E: -18.212 +/- (-3.909) vs B: -27.315 +/- (-6.348) and C: -25.647 +/- (-5.694), P < 0.05], reduce the NF-kappaB binding activity (E: 88.89 +/- 19.34 vs B: 141.11 +/- 15.37, C: 112.89 +/- 20.17 and D: 108.89 +/- 20.47, P < 0.05), and lower the serum level of TNF-alpha (E: 1.613 +/- 0.420 ng/mL vs B: 2.892 +/- 0.587 ng/mL, C: 2.346 +/- 0.371 ng/mL and D: 2.160 +/- 0.395 ng/mL, P < 0.05) and IL-6 (E: 0.106 +/- 0.021 ng/mL vs B: 0.140 +/- 0.031 ng/mL and C: 0.137 +/- 0.027 ng/mL, P < 0.05) in mice with liver fibrosis. Rosiglitazone can also substantially reduce the hepatic expression of TGF-beta1, alpha-SMA type I and type III collagen in mice with liver fibrosis.
The activation of PPAR gamma by its ligand can retard liver fibrosis and suggest the use of rosiglitazone for the treatment of liver fibrosis due to Schistosoma japonicum infection.</description><identifier>ISSN: 1007-9327</identifier><identifier>DOI: 10.3748/wjg.14.2905</identifier><identifier>PMID: 18473419</identifier><language>eng</language><publisher>United States: Department of Infectious Disease,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China%Department of Parasitology, Tongji Medical College,Huazhong University of Science and Technology, Wuhan 430022,Hubei Province, China%Department of Surgical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China</publisher><subject>Actins - metabolism ; Animals ; Anthelmintics - pharmacology ; Collagen Type I - metabolism ; Collagen Type III - metabolism ; Disease Models, Animal ; Hypoglycemic Agents - pharmacology ; Interleukin-6 - blood ; Liver - parasitology ; Liver - pathology ; Liver Cirrhosis - parasitology ; Liver Cirrhosis - pathology ; Liver Cirrhosis - prevention & control ; Mice ; NF-kappa B - metabolism ; PPAR gamma - genetics ; PPAR gamma - metabolism ; Praziquantel - pharmacology ; Rapid Communication ; RNA, Messenger - metabolism ; Rosiglitazone ; Schistosoma japonicum ; Schistosomiasis japonica - complications ; Schistosomiasis japonica - drug therapy ; Thiazolidinediones - pharmacology ; Transforming Growth Factor beta1 - metabolism ; Tumor Necrosis Factor-alpha - blood</subject><ispartof>World journal of gastroenterology : WJG, 2008-05, Vol.14 (18), p.2905-2911</ispartof><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><rights>2008 The WJG Press and Baishideng. All rights reserved. 2008</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-eed46a41d12c1e08fe0008ee2746f4c0a10c1201a10fe9a739cd337d085497963</citedby><cites>FETCH-LOGICAL-c408t-eed46a41d12c1e08fe0008ee2746f4c0a10c1201a10fe9a739cd337d085497963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://www.wanfangdata.com.cn/images/PeriodicalImages/wjg/wjg.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2710736/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2710736/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18473419$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Hui</creatorcontrib><creatorcontrib>He, Yong-Wen</creatorcontrib><creatorcontrib>Liu, Wen-Qi</creatorcontrib><creatorcontrib>Zhang, Jing-Hui</creatorcontrib><title>Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum</title><title>World journal of gastroenterology : WJG</title><addtitle>World J Gastroenterol</addtitle><description>To evaluate the effect of rosiglitazone in a murine model of liver fibrosis induced by Schistosoma japonicum infection.
A total of 50 mice were randomly and averagely divided into groups A, B, C, D and E. The mice in group A served as normal controls, while those in the other four groups were infected with Schistosoma japonicum to induce the model of liver fibrosis. Besides, the mice in groups C, D and E were treated with praziquantel, rosiglitazone and praziquantel plus rosiglitazone, respectively. NF-kappaB binding activity and expression of PPAR gamma-mRNA were determined by Western blot assay and real-time quantitative PCR. Radioimmunonassay technique was used to detect the serum content changes of TNF-alpha and IL-6. Histological specimens were stained with HE. Expression of TGF-beta1, a-smooth muscle actin and type I and type III collagen was detected by immunohistochemistry and multimedia color pathographic analysis system.
Inflammation and fibrosis in the rosiglitazone plus praziquantel treatment group (group E) were lightest among the mice infected with Schistosoma (P < 0.05). To further explore the mechanism of rosiglitazone action, we found that rosiglitazone can significantly increase the expression of PPAR gamma [E: -18.212 +/- (-3.909) vs B: -27.315 +/- (-6.348) and C: -25.647 +/- (-5.694), P < 0.05], reduce the NF-kappaB binding activity (E: 88.89 +/- 19.34 vs B: 141.11 +/- 15.37, C: 112.89 +/- 20.17 and D: 108.89 +/- 20.47, P < 0.05), and lower the serum level of TNF-alpha (E: 1.613 +/- 0.420 ng/mL vs B: 2.892 +/- 0.587 ng/mL, C: 2.346 +/- 0.371 ng/mL and D: 2.160 +/- 0.395 ng/mL, P < 0.05) and IL-6 (E: 0.106 +/- 0.021 ng/mL vs B: 0.140 +/- 0.031 ng/mL and C: 0.137 +/- 0.027 ng/mL, P < 0.05) in mice with liver fibrosis. Rosiglitazone can also substantially reduce the hepatic expression of TGF-beta1, alpha-SMA type I and type III collagen in mice with liver fibrosis.
The activation of PPAR gamma by its ligand can retard liver fibrosis and suggest the use of rosiglitazone for the treatment of liver fibrosis due to Schistosoma japonicum infection.</description><subject>Actins - metabolism</subject><subject>Animals</subject><subject>Anthelmintics - pharmacology</subject><subject>Collagen Type I - metabolism</subject><subject>Collagen Type III - metabolism</subject><subject>Disease Models, Animal</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Interleukin-6 - blood</subject><subject>Liver - parasitology</subject><subject>Liver - pathology</subject><subject>Liver Cirrhosis - parasitology</subject><subject>Liver Cirrhosis - pathology</subject><subject>Liver Cirrhosis - prevention & control</subject><subject>Mice</subject><subject>NF-kappa B - metabolism</subject><subject>PPAR gamma - genetics</subject><subject>PPAR gamma - metabolism</subject><subject>Praziquantel - pharmacology</subject><subject>Rapid Communication</subject><subject>RNA, Messenger - metabolism</subject><subject>Rosiglitazone</subject><subject>Schistosoma japonicum</subject><subject>Schistosomiasis japonica - complications</subject><subject>Schistosomiasis japonica - drug therapy</subject><subject>Thiazolidinediones - pharmacology</subject><subject>Transforming Growth Factor beta1 - metabolism</subject><subject>Tumor Necrosis Factor-alpha - blood</subject><issn>1007-9327</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkUtLAzEURrNQrFZX7mUW4kZabx5tZjaCFF8gCD7WIc3caVNmkjGZUfTXm9LiY3W55PDlcD9CjimMuRT5xcdqMaZizAqY7JB9CiBHBWdyQA5iXAEwzidsjwxoLiQXtNgnj08-2kVtO_3lHWZtwHd0XcyaPti0L7HVnTVZZechgTGzruwNltn8M3s2Sxs7H32js5VuvbOmbw7JbqXriEfbOSSvN9cvs7vRw-Pt_ezqYWQE5N0IsRRTLWhJmaEIeYUAkCMyKaaVMKApGMqApllhoSUvTMm5LCGfiEIWUz4kl5vctp83WJokHXSt2mAbHT6V11b9f3F2qRb-XTFJQfJ1wOkm4EO7SruFWvk-uKSs0g1ZkqE5MJqws-0_wb_1GDvV2GiwrrVD30clQbJ8CiKB5xvQpEPFgNWPCwW17madq6hQ624SffJX_5fdFsO_Ac3ljfo</recordid><startdate>20080514</startdate><enddate>20080514</enddate><creator>Chen, Hui</creator><creator>He, Yong-Wen</creator><creator>Liu, Wen-Qi</creator><creator>Zhang, Jing-Hui</creator><general>Department of Infectious Disease,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China%Department of Parasitology, Tongji Medical College,Huazhong University of Science and Technology, Wuhan 430022,Hubei Province, China%Department of Surgical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China</general><general>The WJG Press and Baishideng</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope><scope>5PM</scope></search><sort><creationdate>20080514</creationdate><title>Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum</title><author>Chen, Hui ; He, Yong-Wen ; Liu, Wen-Qi ; Zhang, Jing-Hui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-eed46a41d12c1e08fe0008ee2746f4c0a10c1201a10fe9a739cd337d085497963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Actins - metabolism</topic><topic>Animals</topic><topic>Anthelmintics - pharmacology</topic><topic>Collagen Type I - metabolism</topic><topic>Collagen Type III - metabolism</topic><topic>Disease Models, Animal</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Interleukin-6 - blood</topic><topic>Liver - parasitology</topic><topic>Liver - pathology</topic><topic>Liver Cirrhosis - parasitology</topic><topic>Liver Cirrhosis - pathology</topic><topic>Liver Cirrhosis - prevention & control</topic><topic>Mice</topic><topic>NF-kappa B - metabolism</topic><topic>PPAR gamma - genetics</topic><topic>PPAR gamma - metabolism</topic><topic>Praziquantel - pharmacology</topic><topic>Rapid Communication</topic><topic>RNA, Messenger - metabolism</topic><topic>Rosiglitazone</topic><topic>Schistosoma japonicum</topic><topic>Schistosomiasis japonica - complications</topic><topic>Schistosomiasis japonica - drug therapy</topic><topic>Thiazolidinediones - pharmacology</topic><topic>Transforming Growth Factor beta1 - metabolism</topic><topic>Tumor Necrosis Factor-alpha - blood</topic><toplevel>online_resources</toplevel><creatorcontrib>Chen, Hui</creatorcontrib><creatorcontrib>He, Yong-Wen</creatorcontrib><creatorcontrib>Liu, Wen-Qi</creatorcontrib><creatorcontrib>Zhang, Jing-Hui</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of gastroenterology : WJG</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Hui</au><au>He, Yong-Wen</au><au>Liu, Wen-Qi</au><au>Zhang, Jing-Hui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum</atitle><jtitle>World journal of gastroenterology : WJG</jtitle><addtitle>World J Gastroenterol</addtitle><date>2008-05-14</date><risdate>2008</risdate><volume>14</volume><issue>18</issue><spage>2905</spage><epage>2911</epage><pages>2905-2911</pages><issn>1007-9327</issn><abstract>To evaluate the effect of rosiglitazone in a murine model of liver fibrosis induced by Schistosoma japonicum infection.
A total of 50 mice were randomly and averagely divided into groups A, B, C, D and E. The mice in group A served as normal controls, while those in the other four groups were infected with Schistosoma japonicum to induce the model of liver fibrosis. Besides, the mice in groups C, D and E were treated with praziquantel, rosiglitazone and praziquantel plus rosiglitazone, respectively. NF-kappaB binding activity and expression of PPAR gamma-mRNA were determined by Western blot assay and real-time quantitative PCR. Radioimmunonassay technique was used to detect the serum content changes of TNF-alpha and IL-6. Histological specimens were stained with HE. Expression of TGF-beta1, a-smooth muscle actin and type I and type III collagen was detected by immunohistochemistry and multimedia color pathographic analysis system.
Inflammation and fibrosis in the rosiglitazone plus praziquantel treatment group (group E) were lightest among the mice infected with Schistosoma (P < 0.05). To further explore the mechanism of rosiglitazone action, we found that rosiglitazone can significantly increase the expression of PPAR gamma [E: -18.212 +/- (-3.909) vs B: -27.315 +/- (-6.348) and C: -25.647 +/- (-5.694), P < 0.05], reduce the NF-kappaB binding activity (E: 88.89 +/- 19.34 vs B: 141.11 +/- 15.37, C: 112.89 +/- 20.17 and D: 108.89 +/- 20.47, P < 0.05), and lower the serum level of TNF-alpha (E: 1.613 +/- 0.420 ng/mL vs B: 2.892 +/- 0.587 ng/mL, C: 2.346 +/- 0.371 ng/mL and D: 2.160 +/- 0.395 ng/mL, P < 0.05) and IL-6 (E: 0.106 +/- 0.021 ng/mL vs B: 0.140 +/- 0.031 ng/mL and C: 0.137 +/- 0.027 ng/mL, P < 0.05) in mice with liver fibrosis. Rosiglitazone can also substantially reduce the hepatic expression of TGF-beta1, alpha-SMA type I and type III collagen in mice with liver fibrosis.
The activation of PPAR gamma by its ligand can retard liver fibrosis and suggest the use of rosiglitazone for the treatment of liver fibrosis due to Schistosoma japonicum infection.</abstract><cop>United States</cop><pub>Department of Infectious Disease,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China%Department of Parasitology, Tongji Medical College,Huazhong University of Science and Technology, Wuhan 430022,Hubei Province, China%Department of Surgical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China</pub><pmid>18473419</pmid><doi>10.3748/wjg.14.2905</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1007-9327 |
| ispartof | World journal of gastroenterology : WJG, 2008-05, Vol.14 (18), p.2905-2911 |
| issn | 1007-9327 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2710736 |
| source | MEDLINE; Baishideng "World Journal of" online journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Actins - metabolism Animals Anthelmintics - pharmacology Collagen Type I - metabolism Collagen Type III - metabolism Disease Models, Animal Hypoglycemic Agents - pharmacology Interleukin-6 - blood Liver - parasitology Liver - pathology Liver Cirrhosis - parasitology Liver Cirrhosis - pathology Liver Cirrhosis - prevention & control Mice NF-kappa B - metabolism PPAR gamma - genetics PPAR gamma - metabolism Praziquantel - pharmacology Rapid Communication RNA, Messenger - metabolism Rosiglitazone Schistosoma japonicum Schistosomiasis japonica - complications Schistosomiasis japonica - drug therapy Thiazolidinediones - pharmacology Transforming Growth Factor beta1 - metabolism Tumor Necrosis Factor-alpha - blood |
| title | Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T09%3A34%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rosiglitazone%20prevents%20murine%20hepatic%20fibrosis%20induced%20by%20Schistosoma%20japonicum&rft.jtitle=World%20journal%20of%20gastroenterology%20:%20WJG&rft.au=Chen,%20Hui&rft.date=2008-05-14&rft.volume=14&rft.issue=18&rft.spage=2905&rft.epage=2911&rft.pages=2905-2911&rft.issn=1007-9327&rft_id=info:doi/10.3748/wjg.14.2905&rft_dat=%3Cwanfang_jour_pubme%3Ewjg200818021%3C/wanfang_jour_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70728604&rft_id=info:pmid/18473419&rft_wanfj_id=wjg200818021&rfr_iscdi=true |